XOMA Corporation (XOMA): Price and Financial Metrics


XOMA Corporation (XOMA): $19.01

1.13 (+6.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add XOMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

XOMA POWR Grades


  • Quality is the dimension where XOMA ranks best; there it ranks ahead of 86% of US stocks.
  • XOMA's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • XOMA's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

XOMA Stock Summary

  • XOMA's went public 33.01 years ago, making it older than 88.85% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for XOMA Corp is higher than it is for about merely 5.84% of US stocks.
  • With a year-over-year growth in debt of -98.92%, XOMA Corp's debt growth rate surpasses only 1.63% of about US stocks.
  • Stocks that are quantitatively similar to XOMA, based on their financial statements, market capitalization, and price volatility, are PLBY, BEEM, CHCI, MYTE, and ASM.
  • XOMA's SEC filings can be seen here. And to visit XOMA Corp's official web site, go to www.xoma.com.

XOMA Valuation Summary

  • XOMA's price/sales ratio is 12; this is 215.79% higher than that of the median Healthcare stock.
  • Over the past 243 months, XOMA's price/sales ratio has gone down 69.
  • XOMA's price/sales ratio has moved down 69 over the prior 243 months.

Below are key valuation metrics over time for XOMA.

Stock Date P/S P/B P/E EV/EBIT
XOMA 2021-08-31 12.0 3.0 34.7 20.3
XOMA 2021-08-30 12.1 3.1 35.0 20.5
XOMA 2021-08-27 11.2 2.8 32.4 18.6
XOMA 2021-08-26 11.2 2.8 32.4 18.5
XOMA 2021-08-25 11.0 2.8 31.9 18.2
XOMA 2021-08-24 11.0 2.8 31.8 18.1

XOMA Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 300.24%.
  • Its 2 year net income to common stockholders growth rate is now at -189.7%.
  • The 3 year revenue growth rate now stands at -77.15%.
XOMA's revenue has moved up $35,933,000 over the prior 15 months.

The table below shows XOMA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 38.16 22.678 7.787
2021-09-30 29.797 9.714 5.429
2021-06-30 29.414 10.353 10.156
2021-03-31 28.957 11.458 10.153
2020-12-31 29.385 10.092 13.298
2020-09-30 2.227 -11.734 -12.712

XOMA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XOMA has a Quality Grade of C, ranking ahead of 66.13% of graded US stocks.
  • XOMA's asset turnover comes in at 0.233 -- ranking 184th of 682 Pharmaceutical Products stocks.
  • DARE, WINT, and TCON are the stocks whose asset turnover ratios are most correlated with XOMA.

The table below shows XOMA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.233 1 0.187
2021-06-30 0.252 1 0.254
2021-03-31 0.277 1 0.222
2020-12-31 0.301 1 0.242
2020-09-30 0.025 1 -0.219
2020-06-30 0.116 1 -0.137

XOMA Price Target

For more insight on analysts targets of XOMA, see our XOMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $44.67 Average Broker Recommendation 1.67 (Moderate Buy)

XOMA Stock Price Chart Interactive Chart >

Price chart for XOMA

XOMA Price/Volume Stats

Current price $19.01 52-week high $39.02
Prev. close $17.88 52-week low $16.96
Day low $17.76 Volume 40,226
Day high $19.36 Avg. volume 31,517
50-day MA $22.66 Dividend yield N/A
200-day MA $23.36 Market Cap 217.11M

XOMA Corporation (XOMA) Company Bio


XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.


XOMA Latest News Stream


Event/Time News Detail
Loading, please wait...

XOMA Latest Social Stream


Loading social stream, please wait...

View Full XOMA Social Stream

Latest XOMA News From Around the Web

Below are the latest news stories about XOMA Corp that investors may wish to consider to help them evaluate XOMA as an investment opportunity.

XOMA to Present at Aegis Capital Corp Investor Conference

EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. The conference will be held from February 23-25, 2022, from 8:30 AM until 5:30 PM ET daily, and can be viewed at https://bit.ly/3BoscU

Yahoo | February 17, 2022

XOMA's (NASDAQ:XOMA) investors will be pleased with their massive 368% return over the last five years

While XOMA Corporation ( NASDAQ:XOMA ) shareholders are probably generally happy, the stock hasn't had particularly...

Yahoo | January 21, 2022

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (XOMA or the Company) today announced its Board of Directors has authorized the following cash dividends to holders of XOMAs Series A and Series B Cumulative Preferred Stock:

GlobeNewswire | December 23, 2021

XOMA to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences: Biotech Showcase 2022 held virtually January 10-12 and January 17-19, 2022. Mr. Neal will hold a fireside chat titled, “Royalty Licenses: An Economic Asset Often Ignore

Yahoo | December 21, 2021

XOMA Announces Evolution of Company Leadership and Succession Planning

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director

Intrado Digital Media | December 16, 2021

Read More 'XOMA' Stories Here

XOMA Price Returns

1-mo -7.94%
3-mo -14.33%
6-mo -13.04%
1-year -37.26%
3-year 8.50%
5-year 182.47%
YTD -8.82%
2021 -52.75%
2020 61.65%
2019 115.81%
2018 -64.47%
2017 743.60%

Continue Researching XOMA

Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:

XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0683 seconds.